WuXi Biologics Breaks Ground on China's First Dual-Chamber Lyophilization Manufacturing Site in Chengdu
核心洞察
WuXi Biologics has commenced construction of a 95,000 square meter microbial manufacturing facility in Chengdu, featuring China's first dual-chamber lyophilization production line.
The facility will house a 15,000L fermenter with expansion potential to 60,000L, enabling production of 80-110 drug substance batches annually and over 10 million vials of drug product.
The site will utilize WuXi's EffiX™ microbial expression platform to manufacture diverse biologics including peptides, antibody fragments, and virus-like particles for global commercial distribution.
WuXi Biologics has initiated construction of a state-of-the-art microbial manufacturing facility in Chengdu's Wenjiang district, marking a significant expansion of the company's commercial production capabilities. The 95,000 square meter site represents a major investment in China's biopharmaceutical manufacturing infrastructure and will house the country's first dual-chamber lyophilization production line.
Advanced Manufacturing Capabilities
The facility is designed to accommodate both drug substance and drug product manufacturing across multiple therapeutic modalities. The site will feature a 15,000L fermenter capable of producing 80 to 110 drug substance batches annually, with long-term expansion potential to 60,000L capacity. The drug product facility will include China's first dual-chamber lyophilization production line alongside a vial filling line, delivering an overall manufacturing capacity exceeding 10 million vials annually.
The manufacturing operations will encompass a diverse range of biologics, including peptides, antibody fragments, plasmid DNA, enzymes, cytokines, and virus-like particles. This broad capability positions the facility to serve multiple therapeutic areas and support various stages of product development and commercialization.
EffiX™ Platform Integration
Central to the facility's operations is WuXi Biologics' recently launched microbial expression platform EffiX™, designed for high-yield production of biologics with consistent quality and superior stability. The platform achieves titers exceeding 15 g/L for non-monoclonal antibody recombinant proteins, representing a significant advancement in microbial production efficiency.
The facility incorporates advanced automated systems to ensure regulatory compliance, operational efficiency, and quality standards. Design considerations include energy conservation and sustainability measures, with optimized process development approaches and comprehensive carbon tracking mechanisms to minimize environmental impact while maintaining production standards.
Strategic Commercial Partnerships
WuXi Biologics has secured key partnerships to utilize the new manufacturing capacity. The company will produce VISEN Pharmaceuticals (搜索)' inaugural commercial product, Lonapegsomatropin, a long-acting growth hormone for treating pediatric growth hormone deficiency (搜索). Additionally, WuXi has established a strategic partnership with Virogen Biotechnology (搜索), further expanding its commercial manufacturing portfolio.
These collaborations demonstrate the facility's role in meeting growing demand for advanced biologic therapies and validate WuXi's manufacturing capabilities in the competitive global market.
Timeline and Market Impact
The facility is scheduled to complete GMP release for production by the end of 2026, positioning WuXi Biologics to capitalize on the expanding global microbial products market. Dr. Chris Chen, CEO of WuXi Biologics, emphasized the strategic importance of the investment: "With the booming global market for microbial products presenting unprecedented potential for next-generation therapies, our Chengdu site — with its robust production scale and cutting-edge technologies — is ideally positioned to capitalize on this trend."
The Chengdu facility represents a pivotal milestone in WuXi Biologics' commitment to accelerating development and delivery of innovative therapies to patients worldwide, while significantly enhancing the company's commercial manufacturing capabilities for the global biopharmaceutical market.